Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.
Palmerini E, Lopez Pousa A, Grignani G, Redondo A, Hindi N, Provenzano S, Sebio A, Lopez Martin JA, Valverde C, Martinez Trufero J, Gutierrez A, de Alava E, Aparisi Gomez MP, D'Ambrosio L, Collini P, Bazzocchi A, Moura DS, Ibrahim T, Stacchiotti S, Broto JM. Palmerini E, et al. Among authors: lopez martin ja. Cancer. 2025 Jan 1;131(1):e35628. doi: 10.1002/cncr.35628. Epub 2024 Nov 14. Cancer. 2025. PMID: 39540661 Free PMC article. Clinical Trial.
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.
Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S, Lopez-Pousa A, D'Ambrosio L, Gutierrez A, Perez-Vega H, Encinas-Tobajas V, de Alava E, Collini P, Peña-Chilet M, Dopazo J, Carrasco-Garcia I, Lopez-Alvarez M, Moura DS, Lopez-Martin JA. Martin-Broto J, et al. Among authors: lopez pousa a, lopez alvarez m, lopez martin ja. J Immunother Cancer. 2020 Nov;8(2):e001561. doi: 10.1136/jitc-2020-001561. J Immunother Cancer. 2020. PMID: 33203665 Free PMC article. Clinical Trial.
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial.
Moura DS, Lopez-Marti JM, Benesova I, de Andrea C, di Lernia D, Lacerenza S, Mondaza-Hernandez JL, Martin-Ruiz M, Ramirez-Calvo M, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S, Lopez-Pousa A, Lopez-Guerrero JA, Gutierrez A, Encinas-Tobajas V, Hindi N, Sangiolo D, Lopez-Martin JA, Strizova ZO, Martin-Broto J. Moura DS, et al. Among authors: lopez martin ja. Clin Cancer Res. 2024 Nov 15;30(22):5192-5206. doi: 10.1158/1078-0432.CCR-24-1782. Clin Cancer Res. 2024. PMID: 39283727
Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).
Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, Martinez-Trufero J, Lopez-Martin JA, Correa R, Cruz J, Lopez-Pousa A, Santos A, García Del Muro X, Martin-Broto J. Redondo A, et al. Among authors: martin broto j, lopez pousa a, lopez martin ja. Cancer Chemother Pharmacol. 2017 Dec;80(6):1113-1131. doi: 10.1007/s00280-017-3436-0. Epub 2017 Oct 16. Cancer Chemother Pharmacol. 2017. PMID: 29038849 Free PMC article.
Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Martin-Liberal J, López-Pousa A, Martínez-Trufero J, Martín-Broto J, Cubedo R, Lavernia J, Redondo A, López-Martín JA, Mulet-Margalef N, Sanjuan X, Tirado ÒM, Garcia-Del-Muro X. Martin-Liberal J, et al. Among authors: martin broto j, lopez pousa a, lopez martin ja. Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9. Target Oncol. 2018. PMID: 29177953 Clinical Trial.
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.
Martin-Broto J, Redondo A, Moura DS, Valverde C, Morales JM, Lopez-Pousa A, Martinez-Trufero J, Gutierrez A, Díaz-Beveridge R, Luna P, Martinez-Marin V, Marcilla D, Arribas I, Ledesma P, Lopez-Martin JA, Di Lernia D, Zamora J, Hindi N. Martin-Broto J, et al. Among authors: lopez pousa a, lopez martin ja. Nat Commun. 2022 Oct 21;13(1):6278. doi: 10.1038/s41467-022-33975-6. Nat Commun. 2022. PMID: 36271011 Free PMC article. Clinical Trial.
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A. Martin-Broto J, et al. Among authors: lopez martin ja, lopez guerrero ja. J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16. J Clin Oncol. 2016. PMID: 27185843 Clinical Trial.
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L. Bellmunt J, et al. Among authors: lopez martin ja. Clin Transl Oncol. 2010 Jul;12(7):503-8. doi: 10.1007/s12094-010-0544-2. Clin Transl Oncol. 2010. PMID: 20615828 Clinical Trial.
A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.
Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH. Tabernero J, et al. Among authors: lopez martin ja. Clin Cancer Res. 2011 Oct 1;17(19):6313-21. doi: 10.1158/1078-0432.CCR-11-1101. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831953 Clinical Trial.
83 results